CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations

AbstractThe aim of this study was to explore the clinical features and prognostic significance ofCSF3R mutations in AML patients withCEBPA double mutations (CEBPAdm). One hundred one AML patients withCEBPAdm were retrospectively analyzed in this study. Mutation status ofCSF3R gene, clinical features, and long-term outcomes were analyzed. The frequency ofCSF3R mutations in patients withCEBPAdm was 19.80% (20/101). Patients withCSF3R mutations were associated with a lower platelet (u = 2.728,P = 0.006) and higher leukocytes (u = 3.178,P = 0.001) compared with those with wide-typeCSF3R gene. The 5-year relapse-free survival (RFS) was 18.7% in patients withCSF3R mutations, which was significantly lower than those with wide-typeCSF3R (31.8%) (P = 0.015). The 5-year overall survival (OS) was also significantly different between patients with and withoutCSF3R mutations (17.5% versus 57.4%,P = 0.019). The prevalence ofCSF3R mutations was high in AML patients withCEBPAdm, which indicated a poor prognosis, andCSF3R mutations may be a new potential candidate for prognostically re-stratifying AML patients withCEBPAdm.
Source: Annals of Hematology - Category: Hematology Source Type: research